![conference banner](/images/conference-banner.jpeg)
Abstract
Autoimmune diseases of the nervous system such as myasthenia gravis, inflammatory demyelinating polyneuropathies, multiple sclerosis and others are still not curable. Yet the introduction of modern immune therapies could significantly improve the prospects of many patients affected by these disorders. In addition to steroids and immunosuppression i.v. immunoglobulins are used for treatment of myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Interferons, glatiramer acetate, natalizumab and fingolimod are applied in multiple sclerosis. The ever-improving efficacy of the drugs has to be balanced against the increasing risk of possible severe adverse effects.
Keywords: Nervous system, autoimmune disease, myasthenia gravis, inflammatory demyelinating polyneuropathy, multiple sclerosis, interferon, glatiramerazetat, natalizumab, fingolimod, drugs.
Current Pharmaceutical Design
Title:Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Volume: 18 Issue: 29
Author(s): Karl Vass
Affiliation:
Keywords: Nervous system, autoimmune disease, myasthenia gravis, inflammatory demyelinating polyneuropathy, multiple sclerosis, interferon, glatiramerazetat, natalizumab, fingolimod, drugs.
Abstract: Autoimmune diseases of the nervous system such as myasthenia gravis, inflammatory demyelinating polyneuropathies, multiple sclerosis and others are still not curable. Yet the introduction of modern immune therapies could significantly improve the prospects of many patients affected by these disorders. In addition to steroids and immunosuppression i.v. immunoglobulins are used for treatment of myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Interferons, glatiramer acetate, natalizumab and fingolimod are applied in multiple sclerosis. The ever-improving efficacy of the drugs has to be balanced against the increasing risk of possible severe adverse effects.
Export Options
About this article
Cite this article as:
Vass Karl, Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis, Current Pharmaceutical Design 2012; 18 (29) . https://dx.doi.org/10.2174/138161212802502288
DOI https://dx.doi.org/10.2174/138161212802502288 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Autoimmune Diseases and Infections: A Controversial Relationship
Current Immunology Reviews (Discontinued) Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression
Current HIV Research Advances in the Treatment of Autoimmune Diseases; Cellular Activity, Type-1/Type-2 Cytokine Secretion Patterns and their Modulation by Therapeutic Peptides
Current Medicinal Chemistry CRP and Anti-CRP Autoantibodies in Systemic Lupus Erythematosus
Current Rheumatology Reviews Ulcerative Colitis: Pathogenesis
Current Drug Targets Expression and Function of the Leukocyte Integrins in Medicine
Current Genomics Targeting of Th1-Associated Chemokine Receptors CXCR3 and CCR5 as Therapeutic Strategy for Inflammatory Diseases
Mini-Reviews in Medicinal Chemistry ‘Toll’ Gates for Future Immunotherapy
Current Pharmaceutical Design Biologics in Inflammatory Immune-mediated Systemic Diseases
Current Pharmaceutical Biotechnology Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope
Current Cancer Therapy Reviews Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Immunomodulatory Role of Arsenic in Regulatory T Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets Acquired Hemophilia as Initial Presentation in a Patient with Systemic Lupus Erythematosus
Current Rheumatology Reviews Current Status of Vitamin D Signaling and Its Therapeutic Applications
Current Topics in Medicinal Chemistry Natural Products to Improve Quality of Life Targeting for Colon Drug Delivery
Current Drug Delivery Role of Innate Immunity in Triggering and Tuning of Autoimmune Diabetes
Current Molecular Medicine Modulation of the Immune Response by the Cholera-like Enterotoxins
Current Topics in Medicinal Chemistry Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued) Update on ICOS: A Possible Target for Turning-Off Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)